Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Retained Earnings (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Retained Earnings data on record, last reported at -$274000.0 in Q3 2025.

  • For Q3 2025, Retained Earnings rose 99.96% year-over-year to -$274000.0; the TTM value through Sep 2025 reached -$274000.0, up 99.96%, while the annual FY2024 figure was -$730.7 million, 314854.31% down from the prior year.
  • Retained Earnings reached -$274000.0 in Q3 2025 per TNXP's latest filing, down from -$270000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at -$211000.0 in Q1 2023 and bottomed at -$730.7 million in Q4 2024.
  • Average Retained Earnings over 3 years is -$288.6 million, with a median of -$274000.0 recorded in 2025.
  • Peak YoY movement for Retained Earnings: plummeted 314854.31% in 2024, then surged 99.96% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$232000.0 in 2023, then tumbled by 314854.31% to -$730.7 million in 2024, then skyrocketed by 99.96% to -$274000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$274000.0 in Q3 2025, -$270000.0 in Q2 2025, and -$266000.0 in Q1 2025.